{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:11:14Z","timestamp":1790187074289,"version":"4.1.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lung cancer imposes a substantial global health burden. Although advances in treatment have improved outcomes, increasingly prolonged and complex care may impose considerable financial pressure on patients and their families. We systematically synthesized evidence on financial toxicity (FT) and its associated factors among patients with lung cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Embase, the Cochrane Library, and Scopus were systematically searched through November 2025 for observational studies evaluating FT in patients with lung cancer. Associated factors were synthesized qualitatively and mapped using a harvest plot. Random-effects models were used to pool study-specific FT proportions and mean COST-based scores. Exploratory subgroup analyses were conducted by country income level, disease stage\/treatment setting, and COST-based FT threshold. Heterogeneity was assessed using Cochran\u2019s Q and I\u00b2 statistics. Prediction intervals and leave-one-out analyses were used to evaluate variability and robustness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eighteen studies were included. The pooled proportion of patients meeting study-specific FT definitions across eight studies was 0.55 (95% CI, 0.43\u20130.66), while the pooled mean COST-based score across ten studies was 22.91 (95% CI, 20.57\u201325.25). The pooled FT proportion was numerically lower in high-income than in upper-middle-income countries (0.47 vs 0.61;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.171). FT proportions differed by disease stage\/treatment setting (advanced\/systemic treatment, 0.50; mixed\/all-stage populations, 0.67; surgery-dominant populations, 0.42;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.031). No difference was observed between studies using COST-based thresholds of 21\u201322 and 23\u201325 (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.999). Lower income, inadequate insurance protection, employment disruption, limited savings, and greater out-of-pocket burden were recurring correlates of worse FT. Substantial heterogeneity persisted across analyses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>FT represents an important but highly context-dependent burden among patients with lung cancer. Given the substantial heterogeneity and predominantly cross-sectional evidence, the pooled estimates should be interpreted as exploratory summaries rather than universally applicable benchmarks. Standardized longitudinal assessment and prospective evaluation of risk-stratified interventions are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1896259","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T06:06:41Z","timestamp":1786601201000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Financial toxicity among patients with lung cancer: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Min","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, West China School of Public Health and West China Fourth Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Emeishan People\u2019s Hospital","place":["Emeishan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumeng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Daping Hospital, Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Zhao","sequence":"additional","affiliation":[{"name":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Mianyang, China"]},{"name":"Sichuan Provincial Engineering Research Center of Nuclear Medical Equipment Translation and Application, Mianyang Central Hospital","place":["Mianyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Bian","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People\u2019s Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, China"]},{"name":"Department of Biotherapy,Cancer Center and State Key Laboratory of Biotherapy,West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"102693","DOI":"10.1016\/j.canep.2024.102693","article-title":"Global burden of lung cancer in 2022 and projections to 2050: incidence and mortality estimates from GLOBOCAN","volume":"93","author":"Zhou","year":"2024","journal-title":"Cancer Epidemiol"},{"key":"ref3","article-title":"Latest health spending trends and outlook: balancing resilience and sustainability in challenging times [OECD Health Working Papers] [Internet]. 193rd ed.","author":"Morgan","year":"2026"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"102992","DOI":"10.1016\/j.esmoop.2024.102992","article-title":"ESMO expert consensus statements on the screening and management of financial toxicity in patients with cancer","volume":"9","author":"Carrera","year":"2024","journal-title":"ESMO Open."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1004102","DOI":"10.3389\/fonc.2022.1004102","article-title":"Financial toxicity in lung cancer","volume":"12","author":"Boulanger","year":"2022","journal-title":"Front Oncol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1002\/cncr.28814","article-title":"The development of a financial toxicity patient-reported outcome in cancer: the COST measure","volume":"120","author":"de Souza","year":"2014","journal-title":"Cancer"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1002\/cncr.35367","article-title":"Interventions to mitigate cancer-related medical financial hardship: a systematic review and meta-analysis","volume":"130","author":"Rashidi","year":"2024","journal-title":"Cancer"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1266533","DOI":"10.3389\/fpubh.2023.1266533","article-title":"Describing financial toxicity among cancer patients in different income countries: a systematic review and meta-analysis","volume":"11","author":"Azzani","year":"2023","journal-title":"Front Public Health"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12939-026-02794-2","article-title":"Prevalence and determinants of financial toxicity in patients with colorectal cancer: a systematic review and meta-analysis","volume":"25","author":"Shao","year":"2026","journal-title":"Int J Equity Health"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14639\/0392-100X-N2762","article-title":"Measuring financial toxicity in head and neck cancer: a systematic review","volume":"44","author":"Raggini","year":"2024","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41408-022-00671-z","article-title":"Financial toxicity in hematological malignancies: a systematic review","volume":"12","author":"Ouchveridze","year":"2022","journal-title":"Blood Cancer J"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00520-024-08601-4","article-title":"Measures of financial toxicity in cancer survivors: a systematic review","volume":"32","author":"Thomy","year":"2024","journal-title":"Support Care Cancer"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e1094","DOI":"10.1200\/OP.20.00721","article-title":"Longitudinal trends of financial toxicity in patients with lung Cancer: a prospective cohort study","volume":"17","author":"Friedes","year":"2021","journal-title":"JCO Oncol Pract."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e1110","DOI":"10.1200\/OP.20.00723","article-title":"Unmet care needs and financial hardship in patients with metastatic non-small-cell lung cancer on immunotherapy or chemoimmunotherapy in clinical practice","volume":"17","author":"McLouth","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"4751","DOI":"10.1002\/cam4.5244","article-title":"Financial toxicity of patients with lung cancer in China: results from a National Survey Study","volume":"12","author":"Liu","year":"2023","journal-title":"Cancer Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1097\/SLA.0000000000005926","article-title":"Financial toxicity in patients with resected lung Cancer","volume":"278","author":"Deboever","year":"2023","journal-title":"Ann Surg"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e246872","DOI":"10.1001\/jamanetworkopen.2024.6872","article-title":"Unmet needs, quality of life, and financial toxicity among survivors of lung Cancer","volume":"7","author":"Hsu","year":"2024","journal-title":"JAMA Netw Open"},{"key":"ref18","article-title":"World Bank country and lending groups","year":"2026"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e000332","DOI":"10.1136\/esmoopen-2018-000332","article-title":"Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity","volume":"3","author":"Yoo","year":"2018","journal-title":"ESMO Open"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1245\/s10434-025-17107-0","article-title":"Money matters: the effect of income on postsurgical outcomes in stage IA non-small cell lung Cancer","volume":"32","author":"Jenkins","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.2217\/fon-2018-0874","article-title":"Pretreatment financial toxicity predicts progression-free survival following concurrent chemoradiotherapy for locally advanced non-small-cell lung cancer","volume":"15","author":"Klein","year":"2019","journal-title":"Future Oncol Lond Engl"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.athoracsur.2024.10.023","article-title":"Risk of financial toxicity among adults undergoing lung and esophageal resections for Cancer","volume":"120","author":"Ng","year":"2025","journal-title":"Ann Thorac Surg"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e71256","DOI":"10.1002\/cam4.71256","article-title":"The effect of financial toxicity on the association between perceived social support and negative emotions in post-surgical lung Cancer patients: a cross-sectional study from high-middle income region in China","volume":"14","author":"Xiao","year":"2025","journal-title":"Cancer Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"743","DOI":"10.31662\/jmaj.2024-0289","article-title":"Health insurance and its psychosocial correlates in patients with advanced lung Cancer in Japan","volume":"8","author":"Ito","year":"2025","journal-title":"JMA J"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1177\/10547738251328410","article-title":"Development of a nomogram for predicting financial toxicity risk among lung Cancer patients: a cross-sectional study","volume":"34","author":"Shan","year":"2025","journal-title":"Clin Nurs Res"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1186\/s12885-025-14076-1","article-title":"Potential profile analysis of financial toxicity and its related factors among lung cancer patients","volume":"25","author":"Zhang","year":"2025","journal-title":"BMC Cancer"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.annonc.2019.10.006","article-title":"Financial toxicity in lung cancer: an assessment of magnitude, perception, and impact on quality of life","volume":"31","author":"Hazell","year":"2020","journal-title":"Ann Oncol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.cllc.2018.12.010","article-title":"Financial burden among patients with lung cancer in a publically funded health care system","volume":"20","author":"Ezeife","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/ecc\/6591289","article-title":"Path analysis of influencing factors for financial toxicity in patients with lung cancer","volume":"25","author":"Li","year":"2025","journal-title":"Eur J Cancer Care"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"754199","DOI":"10.3389\/fpubh.2021.754199","article-title":"Assessment of financial toxicity among patients with advanced lung cancer in Western China","volume":"9","author":"Xu","year":"2021","journal-title":"Front Public Health"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e6911","DOI":"10.1002\/cam4.6911","article-title":"Health insurance as a moderator in the relationship between financial toxicity and medical cost-coping behaviors: evidence from patients with lung cancer in China","volume":"13","author":"Cui","year":"2024","journal-title":"Cancer Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.2147\/CMAR.S470862","article-title":"Influence of financial toxicity on the quality of life in lung Cancer patients undergoing immunotherapy: the mediating effect of self-perceived burden","volume":"16","author":"Zhang","year":"2024","journal-title":"Cancer Manag Res"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s00520-023-07647-0","article-title":"Communication of costs and financial burdens between cancer patients and healthcare providers: a qualitative systematic review and meta-synthesis","volume":"31","author":"Kuang","year":"2023","journal-title":"Support Care Cancer"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.6004\/jnccn.2019.7305","article-title":"Financial burdens of cancer treatment: a systematic review of risk factors and outcomes","volume":"17","author":"Smith","year":"2019","journal-title":"J Natl Compr Cancer Netw"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"4645","DOI":"10.1007\/s00520-020-05620-9","article-title":"Financial toxicity associated with a cancer diagnosis in publicly funded healthcare countries: a systematic review","volume":"28","author":"Longo","year":"2020","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"100581","DOI":"10.1016\/j.jcpo.2025.100581","article-title":"Research on the issue of financial toxicity in cancer: a systematic review of the literature","volume":"44","author":"Sideris","year":"2025","journal-title":"J Cancer Policy"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"7159","DOI":"10.1007\/s00520-022-07044-z","article-title":"Financial toxicity of cancer care in low- and middle-income countries: a systematic review and meta-analysis","volume":"30","author":"Donkor","year":"2022","journal-title":"Support Care Cancer"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"557","DOI":"10.6004\/jnccn.2024.7030","article-title":"Impact of a comprehensive financial navigation intervention to reduce cancer-related financial toxicity","volume":"22","author":"Wheeler","year":"2024","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1186\/s12885-021-08697-5","article-title":"Physician-patient communication of costs and financial burden of cancer and its treatment: a systematic review of clinical guidelines","volume":"21","author":"Agarwal","year":"2021","journal-title":"BMC Cancer"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1896259\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T06:06:42Z","timestamp":1786601202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1896259\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":40,"alternative-id":["10.3389\/fpubh.2026.1896259"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1896259","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"article-number":"1896259"}}